Immunohistochemistry Market, By Product (Antibodies, Reagents, Equipment, and Kits), By Application (Diagnostics, Research, and Others), By End User (Hospitals, Diagnostics Laboratories, Academic & Research Institutes, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Mar 2024

Code : CMI4795

Pages :142

Formats :

Excel and PDF

Industry : Pharmaceutical

Immunohistochemistry Market Size and Trends

The immunohistochemistry market is estimated to be valued at USD 2.88 Bn in 2024 and is expected to reach USD 4.49 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.

Immunohistochemistry Market Key Factors

To learn more about this report, request sample copy

The immunohistochemistry market is expected to witness high growth over the forecast period. The major factor driving the growth of this market includes the increasing prevalence of chronic diseases like cancer and cardiovascular diseases. Immunohistochemistry tests are widely used for cancer diagnosis and prognosis. Moreover, technological advancements in this field such as the development of fully automated immunohistochemistry staining systems and digital pathology are expected to provide new growth opportunities for market players. However, highly complex procedural requirements and expensive instrumentation hamper the growth of this market.

Rising Demand for Personalized Medicine

The field of personalized medicine has made enormous progress in recent years. Scientists are gaining deeper understanding of how a person's genetics can impact diseases and treatment outcomes. By studying biomarkers like proteins, physicians can gain valuable insights into what treatment approach may work best for each individual patient. This momentum toward tailored healthcare is driving strong demand for immunohistochemistry testing. Testing tumor tissue samples through immunohistochemistry (IHC) staining allows doctors to examine the presence of specific biomarkers. This reveals whether certain targeted therapies may be effective or whether a patient is likely to respond poorly to a standard treatment approach. As personalized medicine becomes more prevalent, immunohistochemistry is playing a critical role in helping physicians develop personalized care plans and choose the most appropriate intervention for each patient. The ability to analyze patient samples and identify biomarker expressions is fueling the tailoring of treatments at the molecular level. More healthcare organizations are incorporating IHC into standard practice to facilitate data-driven clinical decision making on a personalized basis.

/p>Inorganic growth strategies such as partnerships and collaborations

Market players are actively focusing on partnerships and collaborations, which is expected to drive the growth of the global immunohistochemistry market over the forecast period. For instance, in January 2021, Diaceutics PLC, a company that offers diagnostic tracking, laboratory mapping, testing, and other services, announced a strategic partnership with Canadian Pathology Quality Assurance, a non-profit organization, in order to boost the development of Neurotrophic Tropomyosin Receptor Kinase (NTRK) IHC proficiency testing.